Journal article
Abstract P2-02-04: De-escalation of bone-targeted treatment: Does the number of 6-monthly adjuvant zoledronate infusions received affect treatment efficacy for early breast cancer? A sub-study of ABCSG-12
Abstract
Abstract
Background: The results of the Early Breast Cancer Trialist Group (EBCTCG) meta-analysis (Lancet 2015) led to the widespread adoption of bisphosphonates as adjuvant therapy for postmenopausal early-stage breast cancer (EBC). Despite evaluating multiple bisphosphonate agents and regimens, there was no signal of varying efficacy with different agents, routes of administration or dose/dose intensity. We evaluated the …
Authors
Beltran-Bless A-A; Clemons M; Fesl C; Hlauschek D; Soelkner L; Pond GR; Vandermeer L; Greil R; Balic M; Bjelic-Radisic V
Journal
Cancer Research, Vol. 83, No. 5_Supplement,
Publisher
American Association for Cancer Research (AACR)
Publication Date
March 1, 2023
DOI
10.1158/1538-7445.sabcs22-p2-02-04
ISSN
0008-5472